文献速递心脑血管急症

联邦医疗保险受益者中紫杉醇涂层器械股腘动脉腔内治疗安全性的纵向评估:SAFE-PAD研究

Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study.
PubMed 文献 · JAMA Intern Med · 2021-01-01
一句话结论SAFE-PAD回顾性队列研究显示,在联邦医疗保险受益者中,紫杉醇涂层器械(DCD)用于股腘动脉血运重建的死亡率不劣于非涂层器械(NDCD)(HR 0.95,95%CI 0.94-0.97,非劣效性P<.001)。

SAFE-PAD是一项与美国食品药品监督管理局共同设计的回顾性队列研究,纳入2015年4月1日至2018年12月31日在美国2978家住院和门诊机构接受股腘动脉血运重建、年龄≥66岁的联邦医疗保险按服务收费受益者,比较DCD与NDCD的全因死亡率。共纳入168553例患者,其中70584例(41.9%)接受DCD治疗;中位随访2.72年(四分位距0.87-3.77,最长5.16年)。加权后DCD组与NDCD组全因死亡累积发生率分别为53.8%和55.1%(HR 0.95;95%CI 0.94-0.97;非劣效性P<.001),在预设亚组(包括支架、球囊、伴或不伴CLI、最低四分位合并症)中均未观察到DCD相关危害。结论认为在中位随访2.72年内,DCD在死亡率方面不劣于NDCD,敏感性分析结果稳健,且在各预设亚组中一致。

要点

  • 在168553例年龄≥66岁的联邦医疗保险受益者中,DCD组全因死亡累积发生率为53.8%,NDCD组为55.1%,HR 0.95(95%CI 0.94-0.97),非劣效性P<.001。
  • 预设亚组中未见DCD相关危害:支架亚组HR 0.97(95%CI 0.95-1.00),球囊亚组HR 0.94(95%CI 0.92-0.96)。
  • 伴CLI者HR 0.95(95%CI 0.93-0.97),不伴CLI者HR 0.97(95%CI 0.95-0.99),最低四分位总合并症者HR 0.95(95%CI 0.92-0.99)。
  • 中位随访2.72年(四分位距0.87-3.77,最长5.16年),Cox回归和工具变量分析与主要结果一致。

适用人群与场景

  • 年龄66岁及以上、在股腘动脉血运重建前已加入联邦医疗保险按服务收费项目1年或以上的受益者。
  • 2015年4月1日至2018年12月31日期间在美国2978家住院和门诊机构接受股腘动脉血运重建的患者。
  • 预设亚组包括低风险队列、手术地点、疾病严重程度和器械类型。

研究设计与关键结果

  • 研究类型:回顾性队列研究(SAFE-PAD),与美国食品药品监督管理局共同设计,评估DCD与NDCD死亡率的非劣效性。
  • 样本量与人群:共168553例患者,其中70584例(41.9%)接受DCD治疗;平均(SD)年龄77.0(7.6)岁,女性75744例(44.9%),白人136916/167197例(81.9%),糖尿病85880/168553例(51.0%),吸烟82554/168553例(49.0%),CLI 78665/168553例(45.7%),既往截肢13296/168553例(7.9%)。
  • 主要终点:加权后全因死亡累积发生率DCD组53.8% vs NDCD组55.1%,HR 0.95(95%CI 0.94-0.97),非劣效性P<.001。
  • 关键亚组:支架亚组HR 0.97(95%CI 0.95-1.00),球囊亚组HR 0.94(95%CI 0.92-0.96);CLI亚组HR 0.95(95%CI 0.93-0.97),非CLI亚组HR 0.97(95%CI 0.95-0.99);最低四分位总合并症亚组HR 0.95(95%CI 0.92-0.99)。
  • 敏感性分析:Cox回归和工具变量分析与主要结果一致;采用逆概率加权校正观察到的特征不平衡。
  • 中位随访2.72年(四分位距0.87-3.77;最长5.16年),主要终点评估截至2020年5月31日。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在中位随访2.72年内,DCD在死亡率方面不劣于NDCD,该发现在敏感性分析和预设亚组中一致。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Paclitaxel-coated peripheral devices have been associated with increased mortality, yet this harm signal has not been replicated outside of meta-analyses of small trials.

OBJECTIVE: To provide a longitudinal assessment of the safety of femoropopliteal endovascular treatment with peripheral drug-coated devices (DCDs) among Medicare beneficiaries.

DESIGN, SETTING, AND PARTICIPANTS: SAFE-PAD (Safety Assessment of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices) was a retrospective cohort study designed with the US Food and Drug Administration to evaluate the noninferiority of mortality between DCDs and non-drug-coated devices (NDCDs) for femoropopliteal revascularization performed in 2978 inpatient and outpatient facilities in the US from April 1, 2015, through December 31, 2018. Evaluation of the primary outcome was assessed through May 31, 2020. Participants were Medicare fee-for-service beneficiaries 66 years and older with 1 or more years of enrollment prior to femoropopliteal revascularization. Prespecified subgroups included low-risk cohorts, procedure location, disease severity, and device type. Inverse probability weighting was used to account for imbalances of observed characteristics. Sensitivity analyses were used to evaluate the potential influence of unmeasured confounding.

EXPOSURES: Treatment with DCDs vs NDCDs as determined by claims codes during the index procedure.

MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality. Secondary outcomes included repeated hospitalization, repeated lower extremity revascularization, and lower extremity amputation. Falsification end points were acute myocardial infarction, congestive heart failure, and pneumonia.

RESULTS: Of 168 553 patients, 70 584 (41.9%) were treated with a DCD. The mean (SD) age was 77.0 (7.6) years, 75 744 (44.9%) were female, 136 916 of 167 197 (81.9%) were White individuals, 85 880 of 168 553 (51.0%) had diabetes, 82 554 of 168 553 (49.0%) used tobacco, 78 665 of 168 553 (45.7%) had critical limb ischemia (CLI), and 13 296 of 168 553 (7.9%) had a prior amputation. Median follow-up was 2.72 years (interquartile range, 0.87-3.77; longest, 5.16 years). After weighting, the cumulative incidence of all-cause mortality was 53.8% with DCDs and 55.1% with NDCDs (hazard ratio [HR], 0.95; 95% CI, 0.94-0.97; noninferiority P < .001). Cox regression and instrumental variable analyses were consistent with the primary findings. No harm associated with DCDs was observed among subgroups, including those treated with stents (HR, 0.97; 95% CI, 0.95-1.00) or balloons (HR, 0.94; 95% CI, 0.92-0.96), with or without CLI (CLI: HR, 0.95; 95% CI, 0.93-0.97; non-CLI: HR, 0.97; 95% CI, 0.95-0.99), and those within the lowest quartile of total comorbidities (HR, 0.95; 95% CI, 0.92-0.99).

CONCLUSIONS AND RELEVANCE: In this initial report from the SAFE-PAD cohort study, DCDs were found to be noninferior to NCDCs in respect to mortality through a median follow-up of 2.72 years. This finding remained robust in sensitivity analyses and was consistent across prespecified subgroups.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Secemsky EA, Shen C, Schermerhorn M, et al. Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. JAMA Intern Med. 2021. PMID: 33993204. doi:10.1001/jamainternmed.2021.2738

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。